Which peptides are studied for cognition?

The most cited in the literature are Semax (linked to modulation of neurotrophins such as BDNF and to attention), Selank (a mainly anxiolytic profile via GABAergic and monoaminergic pathways) and Dihexa (an angiotensin IV analog explored for a possible synaptogenic effect). Being studied does not mean they are approved or that a recommended dose exists; they are research material. This answer is educational and not medical advice.

Do they all have the same evidence behind them?

No, and it is an important difference. Semax and Selank have accumulated decades of research, though dominated by Russian literature and small, open-label or non-randomized clinical studies, and are approved as medicines only in Russia. Dihexa lags behind: its published data are almost all preclinical (animals), with no human trials, and part of its foundational literature has been subject to a research-integrity investigation, a retraction and a Notice of Concern, so it should be read with particular caution and as highly experimental.

Why should you be skeptical of peptide nootropics?

Because they coexist with a lot of marketing and the caution signals are several: most striking results are preclinical and do not automatically transfer to humans; much of the favorable evidence comes from specific research environments with limited designs; perceived cognition is highly sensitive to placebo; and cases like Dihexa show that even published literature needs independent replication. Skepticism here means demanding quality evidence, not denying that the field is of interest.

← Guides

Peptides for cognition: an evidence-based overview

Searching for "peptides for cognition" usually leads to lists promising focus, memory or mental clarity as if it were just a matter of picking a vial. The literature tells a less comfortable story: a handful of peptides recur in research on cognition and mood —Semax, Selank and Dihexa are the most cited— but they represent very different mechanisms and, above all, radically uneven levels of evidence. Semax and Selank carry decades of Russian research; Dihexa lives almost entirely in preclinical territory and, on top of that, comes with a research-integrity history that forces you to read its data carefully. This guide is an educational overview of that field: what is being investigated, how solid it is, and why skepticism is not pessimism but method. It is not medical advice, a protocol or a recommendation for use. These compounds are research-use-only (RUO) material and are not approved for human use in the EU, US or UK.

Three peptides, three different mechanisms

The common mistake is to file these compounds under one "peptide nootropics" heading. In the literature they represent different pathways. Semax is a heptapeptide derived from an inactive fragment of adrenocorticotropic hormone (ACTH 4-10), with negligible hormonal activity; research interest centers on its ability, described mainly in animal models, to upregulate the expression of neurotrophic factors such as BDNF and NGF, alongside effects on attention and on dopaminergic and serotonergic signaling. Selank is another heptapeptide, a synthetic analog of tuftsin, with a more anxiolytic described profile: GABAergic and monoaminergic modulation and inhibition of enkephalin-degrading enzymes, without acting as a classic benzodiazepine-receptor agonist. Dihexa is a case apart: not a "classic" peptide but a small molecule designed as a stabilized analog of angiotensin IV, which its originating laboratory proposed potentiates hepatocyte growth factor (HGF) signaling through the c-Met receptor to promote synapse formation. These are different conceptual frameworks —neurotrophins, anxiolysis, synaptogenesis— not interchangeable versions of the same product.

Very uneven levels of evidence

Here is the part "best nootropics" lists tend to omit: the evidence behind each one is not comparable. Semax and Selank have decades of research, but it is dominated by Russian-language literature and small clinical studies, mostly open-label or non-randomized; in fact both are approved as prescription medicines in Russia (Semax for post-stroke rehabilitation, Selank as an anxiolytic), a status not recognized in the West and not equivalent to the large, placebo-controlled randomized trials the EMA or FDA require. Dihexa sits a rung lower: all its published data are preclinical (rodents, zebrafish, cell cultures), with no identified human trials or clinical dosing data. And it carries an added integrity problem: a 2021 Washington State University investigation concluded that a co-author on the original program had altered or fabricated images; a closely related mechanistic paper was retracted in 2025 and Dihexa's foundational paper carries a published PubMed Notice of Concern. Some later independent support exists (a Chinese group unaffiliated with that program reported memory improvements in an Alzheimer's mouse model), but it remains animal-only and not broadly replicated. The practical takeaway: you cannot place all three at the same level of confidence.

Why be skeptical of peptide nootropics

The nootropics field lives alongside a lot of marketing, and peptides are no exception. Several signals invite caution. First, the gap between preclinical and human: "BDNF rose in a rodent's hippocampus" or "a memory task improved in mice" is not the same as "it improves your focus," because doses, routes of administration and biology do not automatically transfer. Second, source bias: much of the favorable evidence for Semax and Selank comes from a single research environment and with limited study designs, which does not invalidate it but does mean it should be read as preliminary. Third, the placebo effect and subjectivity: perceived cognition is especially sensitive to expectation, so enthusiastic forum testimonials are not evidence. And fourth, the Dihexa case is a reminder that even published literature can fail and needs independent replication. Being skeptical here does not mean denying that the field is interesting —it is— but demanding the same quality of proof you would ask of anything you take expecting an effect on your brain.

The RUO framework and safety

Outside their Russian prescription channels, these compounds are sold as research material —Research Use Only (RUO)— and that framework is not a technicality. It means they have not passed the approval process a medicine requires in the EU, US or UK, that no human doses are established by a regulatory authority, and that long-term safety profiles are generally poorly characterized; in Dihexa's case, no human safety, tolerability or pharmacokinetic data exist at any dose at all. On top of this comes the supply-chain problem: sold outside any pharmaceutical control, material obtained online carries a risk of misidentification, contamination, unguaranteed sterility or incorrect concentration. That is why an honest overview stops at mechanism and evidence and does not cross into protocols or doses. Knowing how to read a certificate of analysis (CoA) from an independent third party —identity and purity by HPLC, quantification by mass spectrometry— is part of critical thinking in this area, but any decision affecting your health belongs to a qualified healthcare professional, not to an educational guide.

Frequently asked questions

Which peptides are studied for cognition?: The most cited in the literature are Semax (linked to modulation of neurotrophins such as BDNF and to attention), Selank (a mainly anxiolytic profile via GABAergic and monoaminergic pathways) and Dihexa (an angiotensin IV analog explored for a possible synaptogenic effect). Being studied does not mean they are approved or that a recommended dose exists; they are research material. This answer is educational and not medical advice.
Do they all have the same evidence behind them?: No, and it is an important difference. Semax and Selank have accumulated decades of research, though dominated by Russian literature and small, open-label or non-randomized clinical studies, and are approved as medicines only in Russia. Dihexa lags behind: its published data are almost all preclinical (animals), with no human trials, and part of its foundational literature has been subject to a research-integrity investigation, a retraction and a Notice of Concern, so it should be read with particular caution and as highly experimental.
Why should you be skeptical of peptide nootropics?: Because they coexist with a lot of marketing and the caution signals are several: most striking results are preclinical and do not automatically transfer to humans; much of the favorable evidence comes from specific research environments with limited designs; perceived cognition is highly sensitive to placebo; and cases like Dihexa show that even published literature needs independent replication. Skepticism here means demanding quality evidence, not denying that the field is of interest.

✓ Last reviewed · 2026-07-24